CoChat

Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial

Open access
Gunn, David, Fried, Ron, Lalani, Rabia, Farrin, Amanda, Holloway, Ivana, Morris, Tom, Olivier, Catherine, Kearns, Rachael, Corsetti, Maura, Scott, Mark, Farmer, Adam, Emmanuel, Anton, Whorwell, Peter, Yiannakou, Yan, Sanders, David, Mclaughlin, John, Kapur, Kapil, Eugenicos, Maria, Akbar, Ayesha, Trudgill, Nigel, Houghton, Lesley, Dinning, Phil G., Ford, Alexander C., Aziz, Qasim, Spiller, Robin · 2019 · Trials
Cited by 16

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

BACKGROUND: receptor antagonist, has had an excellent safety record for over 20 years as an antiemetic, yet is not widely used in the treatment of IBS-D. It has, however, been shown to slow colonic transit and in a small randomised, placebo-controlled, cross-over pilot study, benefited patients with IBS-D. METHODS: This trial is a phase III, parallel group, randomised, double-blind, multi-centre, placebo-controlled trial, with embedded mechanistic studies. Participants (n = 400) meeting Rome IV criteria for IBS-D will be recruited from outpatient and primary care clinics and by social media to receive either ondansetron (dose titrated up to 24 mg daily) or placebo for 12 weeks. Throughout the trial, participants will record their worst abdominal pain, worst urgency, stool frequency, and stool consistency on a daily basis. The primary endpoint is the proportion of "responders" in each group, using Food and Drug Administration (FDA) recommendations. Secondary endpoints include pain intensity, stool consistency, frequency, and urgency. Mood and quality of life will also be assessed. Mechanistic assessments will include whole gut transit, faecal tryptase and faecal bile acid concentrations at baseline and between weeks 8 and 11. A subgroup of participants will also undergo assessment of sensitivity (n = 80) using the barostat, and/or high-resolution colonic manometry (n = 40) to assess motor patterns in the left colon and the impact of ondansetron. DISCUSSION: The TRITON trial aims to assess the effect of ondansetron across multiple centres. By defining ondansetron's mechanisms of action we hope to better identify patients with IBS-D who are likely to respond. TRIAL REGISTRATION: ISRCTN, ISRCTN17508514 , Registered on 2 October 2017.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13063-019-3562-6

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 16

Metadata

Authors
Gunn, D., Fried, R., Lalani, R., Farrin, A., Holloway, I., Morris, T., Olivier, C., Kearns, R., Corsetti, M., Scott, M., Farmer, A., Emmanuel, A., Whorwell, P., Yiannakou, Y., Sanders, D., Mclaughlin, J., Kapur, K., Eugenicos, M., Akbar, A., Trudgill, N., Houghton, L., Dinning, P. G., Ford, A. C., Aziz, Q., & Spiller, R.
Venue
Trials
Published
2019-08-20
Volume
20
Issue
1
Pages
517-517
ISSN
1745-6215 (ISSN-L)
OpenAlex
W2969428984
Cited by
16
References
6
FWCI
2.13
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. https://app.cochat.ai/papers/10.1186/s13063-019-3562-6
The paper
Gunn, D., Fried, R., Lalani, R., Farrin, A., Holloway, I., Morris, T., Olivier, C., Kearns, R., Corsetti, M., Scott, M., Farmer, A., Emmanuel, A., Whorwell, P., Yiannakou, Y., Sanders, D., Mclaughlin, J., Kapur, K., Eugenicos, M., Akbar, A., . . . Spiller, R. (2019). Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. Trials. https://doi.org/10.1186/s13063-019-3562-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.